LGD 3303

LGD 3303 is a selective androgen receptor modulator (SARM; K_i = 0.9 nM).¹ It selectively binds to the androgen receptor over the mineralocorticoid, glucocorticoid, and progesterone receptors (K_is = 1,261, 581, and 136 nM, respectively). LGD 3303 also selectively activates the androgen receptor over the mineralocorticoid and progesterone receptors in reporter assays using CV-1 cells (EC₅₀s = 3.6, 3,695, and 2,233 nM, respectively). It increases levator ani muscle mass, but not prostate muscle mass, in orchiectomized (ORDX) rats at 3 mg/kg per day. LGD 3303 increases body weight and gastrocnemius mass, bone mineral content and density in the lumbar spine and mid-femur, and bone formation rate in ovariectomized (OVX) rats. It increases time spent near male rats by sexually experienced, hormone-primed OVX female rats but decreases time spent near male rats by sexually naïve, hormone-primed OVX female rats, in sexual preference tests.²

WARNING This product is not for human or veterinary use.

1. Vajda, E.G., Hogue, A., Griffiths, K.N., et al. Combination treatment with a selective androgen receptor modulator (SARM) and a bisphosphonate has additive effects in osteopenic female rats. J. Bone Miner. Res. 24(2), 231-240 (2009).

2. Kudwa, A.E., López, F.J., McGivern, R.F., et al. A selective androgen receptor modulator enhances male-directed sexual preference, proceptive behavior, and lordosis behavior in sexually experienced, but not sexually naive, female rats. Endocrinology 151(6), 2659-2668 (2010).